Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (September 2016)
26 slides from Stablecoin Development's investor presentation, September 2016
Slide 1: NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market September 2016 NYSE MKT: NBY www.novabay.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: Strategic Focus on Eye Care
Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa
Slide 4: The Foundation of NovaBay's Technology
The Foundation of NovaBay’s Technology White Blood Cell in Action Invading Microbe White Blood Cell Red Blood Cells Neutrox™ NovaBay’s proprietary, pure Hypochlorous Acid solution 4
Slide 5: Does not generate resistance; removal; anti-biofilm
Does not ✓ generate Resistance ✓ Removal Bacterial ✓ Mechanical Debridement ✓ Anti-biofilm Activity ✓ Anti-Toxin 5
Slide 6: 41 Million Potential Patients in U.S.
41 Million Potential Patients in U.S. 6
Slide 7: What is Blepharitis?
What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease Signs and symptoms ‒ Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation High incidence ‒ 37% of patients seen by ophthalmologists ‒ 47% of patients seen by optometrists Most common cause is st
Slide 8: Case Study – Compelling Results with Avenova
Case Study – Compelling Results with 8
Slide 9: Only two Ingredients = Pure Hypochlorous Acid + Saline
Only two Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Water , PEG-80 Sorbitan Water , PEG 80 , Sorbitan Water, Poloxamer, non-foaming Water, Water USP Laurate , Sodium Laurate , Sodium Polyethylene, pH balanced Cocamidopropyl
Slide 10: Growing Commercial Presence
Growing Commercial Presence 10
Slide 11: Avenova Daily Lid & Lash Hygiene
mm a Avenova’ |} Daily Lid & Lash Hygiene “Neutrox N®vaBay
Slide 12: Addressing Major U.S. Markets
Addressing Major U.S. Markets 12
Slide 13: Market Coverage
Market Coverage 43 Direct Medical Reps In Key Metro Areas Northeast (11): Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago-No, Chicago-So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel
Slide 14: Net Sales ($000)
2,578 Net Sales ($000) Prescriptions 1,664 Direct Buy & Bill Sales 1,580 1,366 465 1,118 553 321 806 122 465 797 1,115 40 684 914 813 425 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016
Slide 15: Driving Toward Operating Cash-Flow Breakeven in 2016
15 Driving Toward Operating Cash-Flow Breakeven in 2016 Combination of Growing Avenova Sales, GPM and Cost Reductions 500 - Breakeven (500) (1,000) (1,500) (2,000) (2,441) (2,500) (2,843) (2,982) (3,000) (3,487) (3,500) (3,786) (4,150) (4,078) (4,113) (4,000) (4,661) (4,624) (4,500) (4,867) (4,859)
Slide 16: Avenova Phased Commercial Strategy
Avenova Phased Commercial Strategy 16
Slide 17: Avenova Phased Commercial Strategy
Avenova Phased Commercial Strategy Phase 1 – Initial Launch ‒ 2015 launch targeted two sales channels at introductory pricing 1. Sales Reps detailing directly to MD’s and OD’s - Primary emphasis - Most efficient approach to seed the market 2. Prescription sales - Once doctors comfortable with prod
Slide 18: Reimbursement
Reimbursement Insurance Coverage Continues to Grow Insurance plan coverage nearly tripled from 34% to >90% in 2016 Coverage essential to implement value pricing model 18
Slide 19: Key Opinion Leader Endorsements
Key Opinion Leader Endorsements 19
Slide 20: KOL from Across U.S. Support
KOL from Across U.S. Support Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chap
Slide 21: KOLs from Across U.S. Support
KOLs from Across U.S. Support Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry-Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally r
Slide 22: Advertising and Collateral Marketing Materials
Advertising Placements in Top Trade Journals Collateral Marketing Materials 22 22
Slide 23: Interactive Website
Interactive Website Find a Physician Find a Pharmacy 23
Slide 24: Financial Overview
Financial Overview Million Market Cap (8/16/16) $44 Cash (6/30/16) $3.5 (Excludes $4 million Financing proceeds received in July) Debt $0 Shares Outstanding 11 (Excludes 4.5M Warrants and 1.5M Stock Options)
Slide 25: Strategic Focus on Eye Care
Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa
Slide 26: NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market NYSE MKT: NBY www.novabay.com August, 2016
NovaBay Pharmaceuticals — Investor Presentation (September 2016) on 6ix